Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients

References

• Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• d’Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. Aids. 1998;12(13):1631–1637.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study Swiss HIV Cohort Study. Lancet. 1999;353(9156):863–868.
   PubMed Web of Science ®Google Scholar
• Ahoua L, Guenther G, Pinoges L, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009;9:81.
   PubMed Web of Science ®Google Scholar
• De Maat MM, Huitema AD, Mulder JW, et al. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther Drug Monit. 2003;25(3):367–373.
   PubMed Web of Science ®Google Scholar
• Johnston V, Cohen K, Wiesner L, et al. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014;209(5):711–720.
   PubMed Web of Science ®Google Scholar
• Zdanowicz MM. The pharmacology of HIV drug resistance. Am J Pharm Educ. 2006;70(5):100.
   PubMed Web of Science ®Google Scholar
• Guiard-Schmid JB, Poirier JM, Meynard JL, et al. High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother. 2003;47(3):986–990.
   PubMed Web of Science ®Google Scholar
• Gunda DW, Kasang C, Kidenya BR, et al. Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania. PLoS One. 2013;8(9):e75118.
   PubMed Web of Science ®Google Scholar
• Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1–10.
   PubMedGoogle Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–1276.
   PubMed Web of Science ®Google Scholar
• Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother. 1994;28(12):1335–1339.
   PubMed Web of Science ®Google Scholar
• Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta. 2001;313(1–2):241–253.
   PubMed Web of Science ®Google Scholar
• Donnerer J, Haas BJ, Kessler HH. Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir. Pharmacology. 2008;82(4):287–292.
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. Aids. 2002;16(4):551–560.
   PubMed Web of Science ®Google Scholar
• Langmann P, Zilly M, Weissbrich B, et al. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir. Eur J Med Res. 2000;5(2):59–62.
   PubMedGoogle Scholar
• Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. Aids. 2000;14(10):1333–1339.
   PubMed Web of Science ®Google Scholar
• Langmann P, Weissbrich B, Desch S, et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur J Med Res. 2002;7(7):309–314.
   PubMed Web of Science ®Google Scholar
• De Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003;42(6):599–605.
   PubMed Web of Science ®Google Scholar
• Dahri K, Ensom MH. Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin Pharmacokinet. 2007;46(2):109–132.
   PubMed Web of Science ®Google Scholar
• Bazzoli C, Jullien V, Le Tiec C, et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet. 2010;49(1):17–45.
   PubMed Web of Science ®Google Scholar
• Molto J, Blanco A, Miranda C, et al. Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol. 2006;62(5):560–566.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Baldelli S, Castoldi S, et al. Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint. Aids. 2014;28(16):2477–2480.
   PubMed Web of Science ®Google Scholar
• Rezk NL, Tidwell RR, Kashuba AD. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805(2):241–247.
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2016. [cited 2016 Jan]. Available from: https://aidsinfo.nih.gov/
   Google Scholar
• Van Luin M, Kuks PF, Burger DM. Use of therapeutic drug monitoring in HIV disease. Curr Opin HIV AIDS. 2008;3(3):266–271.
   PubMed Web of Science ®Google Scholar
• Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. Aids. 2003;17(8):1157–1165.
   PubMed Web of Science ®Google Scholar
• Best BM, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007;46(4):433–442.
   PubMed Web of Science ®Google Scholar
• Albrecht M, Mukherjee AL, Tierney C, et al. A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study. HIV Clin Trials. 2011;12(4):201–214.
   PubMed Web of Science ®Google Scholar
• Demeter LM, Jiang H, Mukherjee AL, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. Aids. 2009;23(3):357–368.
   PubMed Web of Science ®Google Scholar
• Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004;5(5):352–359.
   PubMed Web of Science ®Google Scholar
• Clevenbergh P, Garraffo R, Durant J, et al. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. Aids. 2002;16(17):2311–2315.
   PubMed Web of Science ®Google Scholar
• Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) – a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr. 2006;41(4):461–467.
   PubMed Web of Science ®Google Scholar
• Liu X, Ma Q, Zhang F. Therapeutic drug monitoring in highly active antiretroviral therapy. Expert Opin Drug Saf. 2010;9(5):743–758.
   PubMed Web of Science ®Google Scholar
• Pretorius E, Klinker H, Rosenkranz B. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther Drug Monit. 2011;33(3):265–274.
   PubMed Web of Science ®Google Scholar
• Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis. 2006;6(4):215–225.
   PubMed Web of Science ®Google Scholar
• Ribera E, Lopez-Cortes LF, Soriano V, et al. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation? Enferm Infecc Microbiol Clin. 2005;23(Suppl 2):41–67.
   PubMedGoogle Scholar
• La Porte C. Inhibitory quotient in HIV pharmacology. Curr Opin HIV AIDS. 2008;3(3):283–287.
   PubMed Web of Science ®Google Scholar
• Piscitelli SC. The role of therapeutic drug monitoring in the management of HIV-infected patients. Curr Infect Dis Rep. 2002;4(4):353–358.
   PubMedGoogle Scholar
• Duval X, Lamotte C, Race E, et al. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother. 2002;46(2):570–574.
   PubMed Web of Science ®Google Scholar
• Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother. 2002;46(12):3907–3916.
   PubMed Web of Science ®Google Scholar
• Mallolas J, Blanco J, Labarga P, et al. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir the CIVSA study. HIV Med. 2007;8(4):226–233.
   PubMed Web of Science ®Google Scholar
• Molto J, Santos JR, Perez-Alvarez N, et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008;52(11):3928–3932.
   PubMed Web of Science ®Google Scholar
• Winston A, Hales G, Amin J, et al. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. Aids. 2005;19(13):1393–1399.
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2003;47(2):594–600.
   PubMed Web of Science ®Google Scholar
• Barrail-Tran A, Morand-Joubert L, Poizat G, et al. Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen. Antimicrob Agents Chemother. 2008;52(5):1642–1646.
   PubMed Web of Science ®Google Scholar
• Cleijsen RM, Van De Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother. 2007;60(4):897–900.
   PubMed Web of Science ®Google Scholar
• Pellegrin I, Breilh D, Coureau G, et al. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Antimicrob Agents Chemother. 2007;51(4):1473–1480.
   PubMed Web of Science ®Google Scholar
• Breilh D, Pellegrin I, Rouzés A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). Aids. 2004;18(9):1305–1310.
   PubMed Web of Science ®Google Scholar
• De Requena DG, Gallego O, Valer L, et al. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses. 2004;20(3):275–278.
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Cohen-Codar I, King MS, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2005;49(5):1720–1726.
   PubMed Web of Science ®Google Scholar
• Torti C, Uccelli MC, Quiros-Roldan E, et al. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. J Clin Virol. 2006;35(4):414–419.
   PubMed Web of Science ®Google Scholar
• Gianotti N, Galli L, Danise A, et al. Ability of different lopinavir genotypic inhibitory quotients to predict 48‐week virological response in highly treatment‐experienced HIV‐infected patients receiving lopinavir/ritonavir. J Med Virol. 2006;78(12):1537–1541.
   PubMed Web of Science ®Google Scholar
• Maillard A, Chapplain J-M, Tribut O, et al. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir–ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients. J Clin Virol. 2007;38(2):131–138.
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2004;48(12):4687–4692.
   PubMed Web of Science ®Google Scholar
• Valer L, De Mendoza C, Soriano V. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. J Med Virol. 2005;77(4):460–464.
   PubMed Web of Science ®Google Scholar
• De Requena DG, Bonora S, Calcagno A, et al. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. Antimicrob Agents Chemother. 2008;52(3):1066–1071.
   PubMed Web of Science ®Google Scholar
• De Requena DG, Bonora S, Viganò O, et al. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. J Antimicrob Chemother. 2011;66(1):192–200.
   PubMed Web of Science ®Google Scholar
• Moltó J, Valle M, Santos JR, et al. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients. Antivir Ther. 2010;15(2):219–225.
   PubMed Web of Science ®Google Scholar
• Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–362.
   PubMed Web of Science ®Google Scholar
• D’Avolio A, Pensi D, Baietto L, et al. Therapeutic drug monitoring of intracellular anti-infective agents. J Pharm Biomed Anal. 2014;101:183–193.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102–108.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, D’Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. Aids. 2010;24(7):1064–1066.
   PubMed Web of Science ®Google Scholar
• Avihingsanon A, Sophonphan J, Thammajaruk N, et al. Plasma tenofovir concentrations and proximal tubular dysfunction in HIV-infected adults receiving tenofovir in Thailand. J AIDS Clin Res. 2015;6(7):1–7.
   PubMedGoogle Scholar
• Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013;16:1–14.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids. 2001;15(1):71–75.
   PubMed Web of Science ®Google Scholar
• Group ES. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015;15(7):793–802.
   PubMed Web of Science ®Google Scholar
• Dickinson L, Amin J, Else L, et al. Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naive HIV-infected patients: results of the ENCORE1 study. Clin Pharmacol Ther. 2015;98(4):406–416.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Marinaro L, Nozza S, et al. Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. Antiviral Res. 2014;108:44–47.
   PubMed Web of Science ®Google Scholar
• Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl). 2015;7:95–104.
   PubMedGoogle Scholar
• De Nicolo A, Simiele M, Calcagno A, et al. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. Antimicrob Agents Chemother. 2014;58(7):4042–4047.
   PubMed Web of Science ®Google Scholar
• Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):4–9.
   PubMed Web of Science ®Google Scholar
• Cooper CL, Van Heeswijk RP, Gallicano K, et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36(12):1585–1592.
   PubMed Web of Science ®Google Scholar
• Mathias A, German P, Murray B, et al. Pharmacokinetics and pharmacodynamics of GS‐9350: a novel pharmacokinetic enhancer without anti‐HIV activity. Clin Pharmacol Ther. 2010;87(3):322–329.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1–infected patients: week 48 results. J Infect Dis. 2013;208(1):32–39.
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Opsomer M, Timmers M, et al. Pharmacokinetics of darunavir in fixed‐dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol. 2014;54(8):949–957.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Gibbons S, Khoo S, et al. Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71(7):1755–1758.
   PubMed Web of Science ®Google Scholar
• Crutchley RD, Guduru RC, Cheng AM. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV/AIDS (Auckland, NZ). 2016;8:47.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. HIV Med. 2010;11(5):326–333.
   PubMed Web of Science ®Google Scholar
• Duval X, Mentre F, Rey E, et al. Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen – ANRS 111 trial. Fundam Clin Pharmacol. 2009;23(4):491–500.
   PubMed Web of Science ®Google Scholar
• Duval X, Peytavin G, Albert I, et al. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HIV Med. 2004;5(4):307–313.
   PubMed Web of Science ®Google Scholar
• Casado JL, Moreno S, Hertogs K, et al. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. Aids. 2002;16(1):47–52.
   PubMed Web of Science ®Google Scholar
• Falkensammer B, Fasser W, Scherer K, et al. Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1. Int J Immunopathol Pharmacol. 2005;18(1):145–154.
   PubMed Web of Science ®Google Scholar
• Lotsch J, Harder S, Sturmer M, et al. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007;51(9):3264–3272.
   PubMed Web of Science ®Google Scholar
• Sadler BM, Gillotin C, Lou Y, et al. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother. 2001;45(1):30–37.
   PubMed Web of Science ®Google Scholar
• Gorowara M, Burger D, Hill A, et al. Pharmacokinetics of low-dose protease inhibitors and efavirenz in low-and middle-income countries. Curr Opin HIV AIDS. 2010;5(1):90–96.
   PubMed Web of Science ®Google Scholar
• Avihingsanon A, Lugt J, Kerr S, et al. A low dose of ritonavir‐boosted atazanavir provides adequate pharmacokinetic parameters in HIV‐1‐infected Thai adults. Clin Pharmacol Ther. 2009;85(4):402–408.
   PubMed Web of Science ®Google Scholar
• Boyd M, Mootsikapun P, Burger D, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther. 2005;10(2):301–307.
   PubMed Web of Science ®Google Scholar
• Acosta EP, Kakuda TN, Brundage RC, et al. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000;30(Suppl 2):S151–159.
   PubMed Web of Science ®Google Scholar
• Boffito M, Jackson A, Amara A, et al. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation. Antimicrob Agents Chemother. 2011;55(9):4218–4223.
   PubMed Web of Science ®Google Scholar
• Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2008;4(5):1023–1033.
   PubMedGoogle Scholar
• Edward P, Acosta J, Daniel R. Antiretroviral pharmacokinetics, resistance testing, and therapeutic drug monitoring. In: Libman H, Makadon HJ, editors. HIV. United States: Philadelphia American College of Physicians; 2007. p. 115–136.
   Google Scholar
• Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19(4):262–276.
   PubMedGoogle Scholar
• Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet. 2002;41(12):959–998.
   PubMed Web of Science ®Google Scholar
• L’Homme R, Warris A, Gibb D, et al. Children with HIV are not small adults: what is different in pharmacology? Curr Opin HIV AIDS. 2007;2(5):405–409.
   PubMed Web of Science ®Google Scholar
• Hirt D, Urien S, Jullien V, et al. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother. 2006;50(3):910–916.
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in pediatrics HIV infection. 2016. [cited 2016 Mar]. Available from: https://aidsinfo.nih.gov/
   Google Scholar
• Jullien V, Urien S, Hirt D, et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother. 2006;50(11):3548–3555.
   PubMed Web of Science ®Google Scholar
• Verweel G, Burger DM, Sheehan NL, et al. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir Ther. 2007;12(4):453–458.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Kabamba D, Cressey TR, et al. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother. 2012;56(10):5374–5380.
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet. 2000;39(4):281–293.
   PubMed Web of Science ®Google Scholar
• Tiemessen CT, Kuhn L. Immune pathogenesis of pediatric HIV-1 infection. Curr HIV/AIDS Rep. 2006;3(1):13–19.
   PubMedGoogle Scholar
• Burger DM. The role of therapeutic drug monitoring in pediatric HIV/AIDS. Ther Drug Monit. 2010;32(3):269–272.
   PubMed Web of Science ®Google Scholar
• Schulte J, Dominguez K, Sukalac T, et al. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004. Pediatrics. 2007;119(4):E900–6.
   PubMed Web of Science ®Google Scholar
• Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet. 2012;51(10):639–659.
   PubMed Web of Science ®Google Scholar
• Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7):512–519.
   PubMed Web of Science ®Google Scholar
• Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5(65):1–5.
   PubMed Web of Science ®Google Scholar
• Maher JE, Goldenberg RL, Tamura T, et al. Albumin levels in pregnancy: a hypothesis – decreased levels of albumin are related to increased levels of alpha-fetoprotein. Early Hum Dev. 1993;34(3):209–215.
   PubMed Web of Science ®Google Scholar
• Matsui DM. Therapeutic drug monitoring in pregnancy. Ther Drug Monit. 2012;34(5):507–511.
   PubMed Web of Science ®Google Scholar
• Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. Aids. 2006;20(15):1931–1939.
   PubMed Web of Science ®Google Scholar
• Fayet-Mello A, Buclin T, Guignard N, et al. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. Antivir Ther. 2013;18(2):171–182.
   PubMed Web of Science ®Google Scholar
• Santini-Oliveira M, Estrela RDE, Veloso VG, et al. Randomized clinical trial comparing the pharmacokinetics of standard- and increased- dosage lopinavir- ritonavir coformulation tablets In HIV-positive pregnant women. Antimicrob Agents Chemother. 2014;58(5):2884–2893.
   PubMed Web of Science ®Google Scholar
• Salem AH, Jones AK, Santini-Oliveira M, et al. No need for lopinavir dose adjustment during pregnancy: a population pharmacokinetic and exposure-response analysis in pregnant and nonpregnant HIV-infected subjects. Antimicrob Agents Chemother. 2016;60(1):400–408.
   Web of Science ®Google Scholar
• Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, et al. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit. 2007;29(2):171–176.
   PubMed Web of Science ®Google Scholar
• Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62(3):309–315.
   PubMed Web of Science ®Google Scholar
• Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007;51(2):783–786.
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011;56(5):412–419.
   PubMed Web of Science ®Google Scholar
• Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquir Immune Defic Syndr. 2010;55(3):345–350.
   PubMed Web of Science ®Google Scholar
• Olagunju A, Bolaji O, Neary M, et al. Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. Pharmacogenet Genomics. 2016;26(8):381–389.
   PubMed Web of Science ®Google Scholar
• Benaboud S, Ekouevi DK, Urien S, et al. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2011;55(1):331–337.
   PubMed Web of Science ®Google Scholar
• Izurieta P, Kakuda TN, Feys C, et al. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med. 2011;12(4):257–258.
   PubMed Web of Science ®Google Scholar
• Tran AH, Best BM, Stek A, et al. Pharmacokinetics of rilpivirine in HIV-infected pregnant women. J Acquir Immune Defic Syndr. 2016;72:289–296; Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Best BM, Burchett S, Li H, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502–511.
   PubMed Web of Science ®Google Scholar
• Colbers AP, Hawkins DA, Gingelmaier A, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. Aids. 2013;27(5):739–748.
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.
   PubMed Web of Science ®Google Scholar
• Rhee MS, Greenblatt DJ. Pharmacologic consideration for the use of antiretroviral agents in the elderly. J Clin Pharmacol. 2008;48(10):1212–1225.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc. 1979;27(1):20–22.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Kerzner L. Age effects on alpha-1-acid glycoprotein concentration and imipramine plasma protein binding. J Am Geriatr Soc. 1984;32(10):705–708.
   PubMed Web of Science ®Google Scholar
• Hilmer SN, Shenfield GM, Le Couteur DG. Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag. 2005;1(2):151–156.
   PubMedGoogle Scholar
• Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol. 2004;57(5):540–544.
   PubMed Web of Science ®Google Scholar
• Winston A, Jose S, Gibbons S, et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013;68(6):1354–1359.
   PubMed Web of Science ®Google Scholar
• Vanhove GF, Kastrissios H, Gries JM, et al. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997;41(11):2428–2432.
   PubMed Web of Science ®Google Scholar
• Avihingsanon A, Kerr SJ, Punyawudho B, et al. Short communication: aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients. AIDS Res Hum Retroviruses. 2013;29(12):1541–1546.
   PubMed Web of Science ®Google Scholar
• Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009;48(7):931–939.
   PubMed Web of Science ®Google Scholar
• Baxi SM, Greenblatt RM, Bacchetti P, et al. Common clinical conditions – age, low BMI, ritonavir use, mild renal impairment – affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. Aids. 2014;28(1):59–66.
   PubMed Web of Science ®Google Scholar
• Burger D, Teulen M, Eerland J, et al. The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program. Ther Drug Monit. 2011;33(2):239–243.
   PubMed Web of Science ®Google Scholar
• Koehn J, Ho RJ. Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs lopinavir, ritonavir, and tenofovir in plasma. Antimicrob Agents Chemother. 2014;58(5):2675–2680.
   PubMed Web of Science ®Google Scholar
• Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit. 2003;25(3):393–399.
   PubMed Web of Science ®Google Scholar
• Jung BH, Rezk NL, Bridges AS, et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2007;21(10):1095–1104.
   PubMed Web of Science ®Google Scholar
• Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. Aids. 2009;23(4):471–478.
   PubMed Web of Science ®Google Scholar
• Brambilla D, Jennings C, Aldrovandi G, et al. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol. 2003;41(5):1888–1893.
   PubMed Web of Science ®Google Scholar
• Rakhmanina NY, Capparelli EV, Van Den Anker JN, et al. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection. Ther Drug Monit. 2007;29(1):110–117.
   PubMed Web of Science ®Google Scholar
• Gras A, Schneider S, Karasi JC, et al. Evaluation of saliva as an alternative matrix for monitoring plasma zidovudine, lamivudine and nevirapine concentrations in Rwanda. Curr HIV Res. 2011;9(4):223–228.
   PubMed Web of Science ®Google Scholar
• Parienti -J-J, Barrail-Tran A, Duval X, et al. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother. 2013;57(5):2265–2271.
   PubMed Web of Science ®Google Scholar
• Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19(9):825–835.
   PubMed Web of Science ®Google Scholar
• Prasitsuebsai W, Kerr SJ, Truong KH, et al. Using lopinavir concentrations in hair samples to assess treatment outcomes on second-line regimens among Asian children. AIDS Res Hum Retroviruses. 2015;31(10):1009–1014.
   PubMed Web of Science ®Google Scholar
• Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med. 2002;137(8):696–697.
   PubMed Web of Science ®Google Scholar
• Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52(10):1267–1275.
   PubMed Web of Science ®Google Scholar
• Hugen PW, Langebeek N, Burger DM, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr. 2002;30(3):324–334.
   PubMed Web of Science ®Google Scholar
• Mitty JA, Stone VE, Sands M, et al. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis. 2002;34(7):984–990.
   PubMed Web of Science ®Google Scholar